Loading…
Underlying
Underlying Price
$6.01
Type
Call
Strike
9.5
Expiration
Dec 24, 2026
DTE
41d
Moneyness
OTM
Intrinsic
$0.00
IBRX 9.5 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $0.24 | -52.00% | 25 | 587 |
| Nov 20, 2026 | 7d | $0.46 | -30.30% | 73 | 78 |
| Nov 27, 2026 | 14d | $0.75 | +15.38% | 1 | 138 |
| Dec 4, 2026 | 21d | $0.90 | +12.50% | 244 | 249 |
| Dec 11, 2026 | 28d | — | — | 0 | 2 |
| Dec 24, 2026 | 41d | — | — | 0 | 1 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.